Clinical Trial Details
— Status: No longer available
Administrative data
NCT number |
NCT02510079 |
Other study ID # |
20150501 |
Secondary ID |
|
Status |
No longer available |
Phase |
|
First received |
|
Last updated |
|
Study information
Verified date |
November 2021 |
Source |
University of Miami |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Expanded Access
|
Clinical Trial Summary
The primary purpose of this research study is to determine the safety of injecting ones own
Schwann cells to augment sural nerve autografts after a severe, non-lacerating injury to the
sciatic nerve has occurred.
Description:
The secondary purpose of this research project is to evaluate whether transplanted Schwann
cells can enhance recovery of sensory and motor function. Emergency expanded access for a
single patient was granted, as the patient was an ideal candidate for sural nerve repair
augmented by autologous Schwann cells which could be harvested from a relatively small
segment of sensory nerve. The cells were expanded using cell culture techniques and placed
along with the sural nerve grafts wrapped by an FDA approved collagen matrix (Duragen). This
study is being conducted at the Jackson Memorial and the University of Miami health systems.
As a research subject the patient will be in this study for a total of 5 years from the date
receiving Schwann cell transplant augmentation of sural nerve autografts.